In addition, treatment with the Hsp90 inhibitor 17-allylamino-demothoxy geldanamycin (17-AAG) inhibited substantially reduced IRF1 protein levels in MM cells in the presence or absence of IFN-γ (Supplementary Figure 5A), indicating HSP90 as a main factor. This evidence concerns the gene IRF1 and Miyoshi myopathy.